HIC1 regulates tumor cell responses to endocrine therapies

Molecular Endocrinology

Volumn 23, Issue 12, 2009, Pages 2075-2085

  Zhang, Baohua ^a   Faller, Douglas V ^a   Wang, Sheng ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEAVILY METHYLATED IN CANCERS 1; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE 1; TAMOXIFEN; TRANSCRIPTION FACTOR E2F1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER INHIBITION; CELL STRAIN MCF 7; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN INDUCTION; REAL TIME ECHOGRAPHY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; DRUG RESISTANCE, NEOPLASM; E2F TRANSCRIPTION FACTORS; ESTROGEN ANTAGONISTS; GENE EXPRESSION REGULATION; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MITOGEN-ACTIVATED PROTEIN KINASE 8; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TAMOXIFEN;

EID: 73249119200     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2009-0231     Document Type: Article

References (33)

1. Ariazi EA, Ariazi JL, Cordera F, Jordan VC 2006 Estrogen receptors as therapeutic targets in breast cancer. Curr Top Med Chem 6:195-216
2. Wang S, Zhang B, Faller DV 2002 Prohibitin requires Brg-1 and Brm for the repression of E2F and cell growth. EMBO J 21:3019-3028
3. Wang S, Zhang B, Faller DV 2004 BRG1/BRM and prohibitin are required for growth suppression by estrogen antagonists. EMBO J 23:2293-2303
4. Genovese C, Trani D, Caputi M, Claudio PP 2006 Cell cycle control and beyond: emerging roles for the retinoblastoma gene family. Oncogene 25:5201-5209
5. Santen RJ, Fan P, Zhang Z, Bao Y, Song RX, Yue W 2009 Estrogen signals via an extra-nuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive and -resistant breast cancer cells. Steroids 74:586-594
6. Ali S, Coombes RC 2002 Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2:101-112
7. Zhang B, Chambers KJ, Faller DV, Wang S 2007 Reprogramming of the SWI/SNF complex for co-activation or co-repression in prohibitin-mediated estrogen receptor regulation. Oncogene 26:7153-7157
8. Chen WY, Wang DH, Yen RC, Luo J, Gu W, Baylin SB 2005 Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 123:437-448
9. Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, Curto J, Siddiqui N, Gabra H, McLeod HL, Strathdee G, Brown R 2005 CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 65:8961-8967
10. Zhang J, Martins CR, Fansler ZB, Roemer KL, Kincaid EA, Gustafson KS, Heitjan DF, Clark DP 2005 DNA methylation in anal intraepithelial lesions and anal squamous cell carcinoma. Clin Cancer Res 11:6544-6549
11. Chen WY, Baylin SB 2005 Inactivation of tumor suppressor genes: choice between genetic and epigenetic routes. Cell Cycle 4:10-12
12. Ekmekci CG, Gutiérrez MI, Siraj AK, Ozbek U, Bhatia K 2004 Aberrant methylation of multiple tumor suppressor genes in acute myeloid leukemia. Am J Hematol 77:233-240
13. Chen W, Cooper TK, Zahnow CA, Overholtzer M, Zhao Z, Ladanyi M, Karp JE, Gokgoz N, Wunder JS, Andrulis IL, Levine AJ, Mankowski JL, Baylin SB 2004 Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis. Cancer Cell 6:387-398
14. Gustafson KS, Furth EE, Heitjan DF, Fansler ZB, Clark DP 2004 DNA methylation profiling of cervical squamous intraepithelial lesions using liquid-based cytology specimens: an approach that utilizes receiver-operating characteristic analysis. Cancer 102:259-268
15. Zhang B, Chambers KJ, Leprince D, Faller DV, Wang S 2009 Requirement for chromatin-remodeling complex in novel tumor suppressor HIC1-mediated transcriptional repression and growth control. Oncogene 28:651-661
16. Chen WY, Zeng X, Carter MG, Morrell CN, Chiu Yen RW, Esteller M, Watkins DN, Herman JG, Mankowski JL, Baylin SB 2003 Heterozygous disruption of Hic1 predisposes mice to a genderdependent spectrum of malignant tumors. Nat Genet 33:197-202
17. Hayashi M, Tokuchi Y, Hashimoto T, Hayashi S, Nishida K, Ishikawa Y, Nakagawa K, Tsuchiya S, Okumura S, Tsuchiya E 2001 Reduced HIC-1 gene expression in non-small cell lung cancer and its clinical significance. Anticancer Res 21:535-540
18. Rastogi S, Joshi B, Dasgupta P, Morris M, Wright K, Chellappan S 2006 Prohibitin facilitates cellular senescence by recruiting specific corepressors to inhibit E2F target genes. Mol Cell Biol 26:4161-4171
19. Britschgi C, Rizzi M, Grob TJ, Tschan MP, Hügli B, Reddy VA, Andres AC, Torbett BE, Tobler A, Fey MF 2006 Identification of the p53 family-responsive element in the promoter region of the tumor suppressor gene hypermethylated in cancer 1. Oncogene 25: 2030-2039
20. Saeki T, Tsuruo T, Sato W, Nishikawsa K 2005 Drug resistance in chemotherapy for breast cancer. Cancer Chemother Pharmacol 56(Suppl 1):84-89
21. Robertson JF, Come SE, Jones SE, Beex L, Kaufmann M, Makris A, Nortier JW, Possinger K, Rutqvist LE 2005 Endocrine treatment options for advanced breast cancer: the role of fulvestrant. Eur J Cancer 41:346-356
22. Korenjak M, Brehm A 2005 E2F-Rb complexes regulating transcription of genes important for differentiation and development. Curr Opin Genet Dev 15:520-527
23. Nevins JR 2001 The Rb/E2F pathway and cancer. Hum Mol Genet 10:699-703
24. Galderisi U, Cipollaro M, Giordano A 2006 The retinoblastoma gene is involved in multiple aspects of stem cell biology. Oncogene 25:5250-5256
25. Du W, Pogoriler J 2006 Retinoblastoma family genes. Oncogene 25:5190-5200
26. Harbour JW, Dean DC 2000 The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev 14:2393-2409
27. Berk AJ 2005 Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus. Oncogene 24:7673-7685
28. Joshi B, Rastogi S, Morris M, Carastro LM, DeCook C, Seto E, Chellappan SP 2007 Differential regulation of human YY1 and caspase 7 promoters by prohibitin through E2F1 and p53 binding sites. Biochem J 401:155-166
29. Rastogi S, Joshi B, Fusaro G, Chellappan S 2006 Camptothecin induces nuclear export of prohibitin preferentially in transformed cells through a CRM-1-dependent mechanism. J Biol Chem 281: 2951-2959
30. Schiff R, Massarweh S, Shou J, Osborne CK 2003 Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res 9:447S-454S
31. Nicoll G, Crichton DN, McDowell HE, Kernohan N, Hupp TR, Thompson AM 2001 Expression of the hypermethylated in cancer gene (HIC-1) is associated with good outcome in human breast cancer. Br J Cancer 85:1878-1882
32. Pinte S, Guérardel C, Deltour-Balerdi S, Godwin AK, Leprince D 2004 Identification of a second G-C-rich promoter conserved in the human, murine and rat tumor suppressor genes HIC1. Oncogene 23:4023-4031
33. Wang S, Fusaro G, Padmanabhan J, Chellappan SP 2002 Prohibitin co-localizes with Rb in the nucleus and recruits N-CoR and HDAC1 for transcriptional repression. Oncogene 21:8388 - 8396